Eli Lilly: positive data published for peresolimab
(CercleFinance.com) - Eli Lilly reports that the New England Journal of Medicine has published detailed results from the phase 2a study, in which its perezolimab met the primary efficacy endpoint in refractory rheumatoid arthritis.
This data represents the first clinical evidence that stimulation of the endogenous PD-1 inhibitory pathway may be an effective approach to treating rheumatological diseases, the pharmaceutical company said.
Side events were similar in the peresolimab and placebo groups. These data were first presented in abstract form at the American College of Rheumatology (ACR) annual meeting in November 2022.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This data represents the first clinical evidence that stimulation of the endogenous PD-1 inhibitory pathway may be an effective approach to treating rheumatological diseases, the pharmaceutical company said.
Side events were similar in the peresolimab and placebo groups. These data were first presented in abstract form at the American College of Rheumatology (ACR) annual meeting in November 2022.
Copyright (c) 2023 CercleFinance.com. All rights reserved.